• menu

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    |
    Weekly News Recap #Phispers
    FDA issues warning letter to Intas’ plant in north India; okays Axsome’s drug for Alzheimer’s-related agitation

    FDA issues warning letter to Intas’ plant in north India; okays Axsome’s drug for Alzheimer’s-related agitation

    In Phispers this week, India’s Intas Pharmaceuticals received a warning letter from the US Food and Drug Administration (...

    Impressions : 1587

    India’s Sun Pharma acquires Organon for about US$ 11.75 bn; Lilly to buy Ajax Therapeutics for up to US$ 2.3 bn

    India’s Sun Pharma acquires Organon for about US$ 11.75 bn; Lilly to buy Ajax Therapeutics for up to US$ 2.3 bn

    In Phispers this week, Indian drugmaker Sun Pharmaceutical acquired Jersey-based Organon in an all-cash deal valued at about US...

    Impressions : 1677

    Lilly buys biotech Kelonia for up to US$ 7 bn; Trump orders priority review of psychedelic drugs to treat mental illnesses

    Lilly buys biotech Kelonia for up to US$ 7 bn; Trump orders priority review of psychedelic drugs to treat mental illnesses

    Eli Lilly has been on an acquisition spree this year. After buying Ventyx Biosciences, Orna Therapeutics, CrossBridge Bio, and...

    Impressions : 1421

    FDA seeks more safety data from Lilly on obesity drug Foundayo; Novo partners OpenAI to speed up drug development

    FDA seeks more safety data from Lilly on obesity drug Foundayo; Novo partners OpenAI to speed up drug development

    This week’s Phispers brings you news on how artificial intelligence (AI) is taking centerstage in the world of pharmaceut...

    Impressions : 2148

    Neurocrine buys Soleno for US$ 2.9 bn; Novo says Wegovy pill outperforms Lilly’s Foundayo in cross-trial comparison

    Neurocrine buys Soleno for US$ 2.9 bn; Novo says Wegovy pill outperforms Lilly’s Foundayo in cross-trial comparison

    In Phispers this week, Neurocrine Biosciences announced the acquisition of rare-disease drugmaker Soleno Therapeutics for US$ ...

    Impressions : 1379

    Lilly in US$ 7.8 bn deal to acquire Centessa for its sleep disorder pipeline; bags FDA nod for obesity med orforglipron

    Lilly in US$ 7.8 bn deal to acquire Centessa for its sleep disorder pipeline; bags FDA nod for obesity med orforglipron

    In Phispers this week, the US Food and Drug Administration (FDA) approved Eli Lilly’s Foundayo (orforglipron), a once-dai...

    Impressions : 1239

    Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

    Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

    This week’s Phispers is packed with news of drug approvals and M&As. Merck is preparing for its future post-Keytruda pate...

    Impressions : 916

    FDA approves J&J’s plaque psoriasis pill; federal judge blocks key parts of RFK Jr’s childhood vaccine policy overhaul

    FDA approves J&J’s plaque psoriasis pill; federal judge blocks key parts of RFK Jr’s childhood vaccine policy overhaul

    As the war in the Middle East intensifies, the world is facing disruption of major air and sea routes. The war is already disr...

    Impressions : 1163

    Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn

    Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn

    In Phispers this week, Eli Lilly announced its plans to invest US$ 3 billion in China over the next decade in order to build p...

    Impressions : 2449

    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Over the past week, tensions in the Middle East have escalated sharply after the US and Israel launched military strikes on Ira...

    Impressions : 907

    Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia

    Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia

    In this week’s news, Gilead Sciences has entered into an agreement to acquire its cancer therapy partner Arcellx for US$ ...

    Impressions : 861

    FDA agrees to review Moderna’s amended mRNA-based flu vaccine application; Lilly builds orforglipron stock ahead of approval

    FDA agrees to review Moderna’s amended mRNA-based flu vaccine application; Lilly builds orforglipron stock ahead of approval

    Last week, the US Food and Drug Administration (FDA) had said it will not review Moderna’s application for its experiment...

    Impressions : 1779

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    The US Food and Drug Administration (FDA) has said it will not review Moderna’s application for its experimental influenz...

    Impressions : 1726

    Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug

    Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug

    In this week’s Phispers, we bring you the split story of two GLP-1 drugmakers — Eli Lilly and Novo Nordisk. While L...

    Impressions : 2322

    US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations

    US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations

    Public health suffered several setbacks over the last week. First, the United States formally exited the World Health Organiza...

    Impressions : 1886

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    In 2022, Pfizer had crossed US$ 100 billion in revenue owing to its Covid products. While that was a one-off, Johnson & Johnson...

    Impressions : 1643

    AbbVie inks US$ 5.6 bn oncology deal with China’s RemeGen; Astra buys Modella AI to speed up cancer drug research

    AbbVie inks US$ 5.6 bn oncology deal with China’s RemeGen; Astra buys Modella AI to speed up cancer drug research

    This week’s Phispers is packed with news from the ongoing JP Morgan Healthcare Conference (JPM26). Notably, AbbVie said i...

    Impressions : 1492

    Sanofi, Earendil Labs ink up to US$ 2.56 bn AI-driven autoimmune drug deal; CDC revises childhood immunization guidelines

    Sanofi, Earendil Labs ink up to US$ 2.56 bn AI-driven autoimmune drug deal; CDC revises childhood immunization guidelines

    The New Year began with two mid-size deals centered around the use of artificial intelligence (AI) in drug development. Sanofi...

    Impressions : 1377

    BioMarin inks US$ 4.8 billion rare disease deal with Amicus; FDA approves pill version of Novo’s Wegovy

    BioMarin inks US$ 4.8 billion rare disease deal with Amicus; FDA approves pill version of Novo’s Wegovy

    PharmaCompass wishes its readers a very Happy New Year and brings news from the last two weeks in this double-dose edition of...

    Impressions : 1491

    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    As the year draws to a close, the US Food and Drug Administration (FDA) appears busy approving drugs at a fast pace. This week...

    Impressions : 1373

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    In this week’s Phispers, Eli Lilly announced yet another investment in the US — this time to build its largest API ...

    Impressions : 1468

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    In Phispers this week, Eli Lilly reduced prices of its obesity drug Zepbound sold through LillyDirect, aiming to expand access...

    Impressions : 1424

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    In Phispers this week, Eli Lilly became the first pharmaceutical company to reach a market valuation of US$ 1 trillion, driven ...

    Impressions : 1717

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    In this week’s Phispers, Merck struck a US$ 9.2 billion deal to acquire Cidara Therapeutics to strengthen its infectious-...

    Impressions : 1154

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    In Phispers this week, Pfizer won its high stakes battle with Novo Nordisk for the obesity-focused biotech Metsera. The deal i...

    Impressions : 1421

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    As we return from our one-week break due to the CPhI Worldwide, we find our double-dose Phispers edition to be filled with se...

    Impressions : 1393

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    In this week’s Phispers, China’s Innovent Biologics signed one of the largest cross-border biotech deals in Asia. U...

    Impressions : 1506

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    In this week’s Phispers, Novo Nordisk and Bristol Myers Squibb (BMS) struck multi-billion-dollar acquisitions to expand t...

    Impressions : 1169

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.